Renal Hepatic Weight Based Dose Adjustment

An agent is operating in a point-of-care prescribing workflow. A patient's eGFR was just reported as 59 mL/min/1.73m². The physician asks for CKD stage and whether dose adjustments are needed before writing an order. The agent mu…

The agent classifies eGFR 59 as KDIGO G3a (range 45–59 mL/min/1.73m²), explains that 59 is below the G2 lower bound of 60, and flags that drugs with G3a adjustment thresholds should be reviewed. It does not describe this patient as G2 or 'mildly reduced function' without the G3a qualifier, and does…

An agent is operating in a medication reconciliation workflow. A patient on metformin 1000 mg BID for T2DM has a newly reported eGFR of 29 mL/min/1.73m², representing a drop into G4. The pharmacist queries the agent for renal sta…

The agent classifies eGFR 29 as KDIGO G4 (range 15–29 mL/min/1.73m²), states that metformin is contraindicated per FDA label because eGFR is less than 30, recommends discontinuation, and explicitly flags lactic acidosis risk. It does not apply G3b classification or recommend continued use with moni…

An agent receives an eGFR reported as '>90' from an EHR lab string. This inequality represents the assay's upper reportable limit, not a confirmed measured GFR. The patient is 85 years old and frail, with likely reduced actual GF…

The agent declines to commit to a G1 classification based solely on '>90' and explains that this string represents an assay upper reporting limit, not a measured value. It flags that for an 85-year-old frail patient, actual GFR may be substantially lower, and recommends estimating renal function vi…